

Oral Naftopidil Suppresses Human Renal-Cell Carcinoma by Inducing G₁ Cell-Cycle Arrest in Tumor and Vascular Endothelial Cells

Yoichi Iwamoto¹, Kenichiro Ishii², Takeshi Sasaki¹, Manabu Kato¹, Hideki Kanda¹, Yasushi Yamada¹, Kiminobu Arima¹, Taizo Shiraishi², and Yoshiki Sugimura¹

Abstract

Renal cell carcinoma (RCC) is an angiogenesis-dependent and hypoxia-driven malignancy. As a result, several targeting agents are being investigated. However, the efficacy of current regimens is generally insufficient for their toxicity and poor overall response rates. We have recently reported that naftopidil exerts growth-inhibitory effects on human prostate cancer cells. In this study, we investigated the biochemical mechanisms by which naftopidil produces growth-inhibitory and antiangiogenic effects on RCC. We first tested the effects of naftopidil on the proliferation of ACHN and Caki-2 RCC cells. Next, we set up a model simulating the tumor microenvironment, in which ACHN cells were grafted onto the renal capsule of mice. We then tested the effects of naftopidil on human umbilical vein endothelial cells' cell proliferation and Matrigel plug vascularization. Finally, to establish the antitumor activity of naftopidil on RCC, we tested the antitumor effects of naftopidil on excised tumor specimens from 20 patients with RCC that were grafted beneath the renal capsule of mice. Naftopidil showed similar *in vitro* growth-inhibitory effects on all cell lines. Fluorescence-activated cell sorting analysis revealed an increase in G₁ cell-cycle arrest in all naftopidil-treated cell lines. *In vivo* tumorigenic studies showed a significant reduction of ACHN tumor weight, Ki-67 index, and microvessel density (MVD) in naftopidil-treated mice. Naftopidil attenuated neovascularization in an *in vivo* Matrigel plug assay. Studies in mouse xenograft models also showed a significant MVD reduction in naftopidil-treated excised human RCC. The growth-inhibitory effects of naftopidil suggest it may be a novel anticancer agent and a potential preventive option for RCC. *Cancer Prev Res*; 6(9); 1000–6. ©2013 AACR.

Introduction

Each year, approximately 270,000 patients are diagnosed with renal cell carcinoma (RCC), resulting in approximately 110,000 deaths, making it the sixth leading cause of cancer-related deaths in Western countries (1, 2). RCC accounts for 80% to 95% of kidney tumors and has poor prognosis when diagnosed at advanced stages; currently, about 30% of patients with RCC have metastatic disease at diagnosis (3).

As RCC is angiogenesis-dependent and hypoxia-driven (4), several angiogenesis-targeting agents, including inhibitors of the mTOR and VEGF pathways, are being actively investigated in preclinical and clinical studies (5, 6). Targeted agents that have recently received approval for clinical use include receptor tyrosine kinase inhibitors (TKI), such

as sorafenib and sunitinib. Although these inhibitors have shown clinical benefit in RCC, they cause a number of side effects. In addition, patients eventually fail these targeted therapies, developing refractory disease. Therefore, development of novel treatment approaches that are well tolerated and improve clinical outcome remains a high priority.

We have previously reported that naftopidil, a selective α 1-adrenoceptor (α 1-AR) antagonist, inhibits tumor growth in PC-3 human prostate cancer cells, induces G₁-phase cell-cycle arrest and decreases microvessel density (MVD; ref. 7) without the α 1-ARs and the α 1-AR signals (8). However, the mechanisms of naftopidil on reducing MVD are still unclear. Clinically, α 1-AR antagonists have been widely used to treat benign prostatic hyperplasia (BPH), a common prostatic disease in elderly men. Recent research has showed exciting anticancer effects of α 1-AR antagonists that are independent of their effects on α 1-AR. Garrison and colleagues reported that an α 1-AR-antagonist, doxazosin, reduced endothelial cell viability, thus suppressing tumor vascularity in prostate cancer xenografts (9). Epidemiologically, Harris and colleagues reported that quinazoline-based α 1-AR antagonists, such as doxazosin and terazosin, significantly decreased prostate cancer incidence (10). In addition, Sakamoto and colleagues found

Authors' Affiliations: Departments of ¹Nephro-Urologic Surgery and Andrology, and ²Oncologic Pathology, Mie University Graduate School of Medicine, Mie, Japan

Corresponding Author: Yoshiki Sugimura, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan. Phone: 81-59-231-5026; Fax: 81-59-231-5203; E-mail: sugimura@clin.medic.mie-u.ac.jp

doi: 10.1158/1940-6207.CAPR-13-0095

©2013 American Association for Cancer Research.

that the α_1 -AR-antagonists doxazosin and DZ-50 significantly reduced RCC metastatic potential (11). These data led us to hypothesize that naftopidil has anticancer activity against RCC, in addition to its effects against prostate cancer.

The principal aim of our study was to determine whether naftopidil has unique growth-inhibitory and antiangiogenic effects on RCC cells. To conduct our study, we present here results of studies using RCC cell lines, *in vitro* and *in vivo*, in 2 different RCC model systems.

Materials and Methods

Materials


Taiho Pharmaceutical Co., Ltd. kindly provided naftopidil and tamsulosin. Monoclonal anti-human Ki-67 antibody was purchased from Dako, rabbit anti-CD31 (ab28364) was from Abcam, rabbit anti-p21 (2947), and rabbit anti-CDK2 (2546) were from Cell Signaling Technology, and monoclonal anti-actin (AC-15) was from Sigma-Aldrich, Inc.

Cell culture and treatment conditions

The human RCC cell lines, ACHN and Caki-2, were obtained from the European Collection of Cell Cultures, a

Public Health England Culture Collection via DS Pharma Biomedical Co., Ltd. The vendor authenticated both cells by the short tandem repeat-PCR method. Human umbilical vein endothelial cells (HUVEC) were from Lonza Walkersville Inc. ACHN cells were cultured in minimum essential medium (Sigma-Aldrich) and Caki-2 cells were cultured in McCoy 5A Medium (MP Biomedicals), both with 10% FBS (Thermo Scientific HyClone). HUVEC cells were cultured in endothelial cell growth medium-2 (EGM-2; EGM-2 Bullet Kit; Lonza Walkersville Inc.) with 5% FBS. For treatment with naftopidil and tamsulosin, ACHN and Caki-2 cells (2.0×10^4 cells/well) were cultured in 12-well plates for 5 days. Test samples (0–15 $\mu\text{mol/L}$) or vehicle (0.1% dimethyl sulfoxide, DMSO) was added on day 2. Cytotoxicity was determined as previously described (7). To investigate whether naftopidil affected endothelial cells, HUVEC cells (2.0×10^3 cells/well) were cultured in 12-well plates for 5 days, and naftopidil (0–40 $\mu\text{mol/L}$) or vehicle (0.1% DMSO) was added on day 2. The cells were cultured for an additional 3 days and cell growth was determined as previously described (12).

Figure 1. Effects of α_1 -AR antagonists on ACHN and Caki-2 cell-cycle. A, ACHN and Caki-2 cells exposed to various concentrations (0, 5, 10, and 15 $\mu\text{mol/L}$) of each α_1 -AR antagonist for 5 days. B, distribution of cell-cycle phases is shown for ACHN (top) and Caki-2 (bottom) cells treated with 50 $\mu\text{mol/L}$ of each α_1 -AR antagonist for 24 hours. C, cell-cycle regulatory protein expression, determined by Western blot analysis. Total cell lysates (30 μg) were Western blotted and probed with antibodies to p21 and CDK2. Protein levels were compared with β -actin loading controls. Values represent the means \pm SD. *, $P < 0.05$; **, $P < 0.01$ versus untreated controls.



Cell-cycle analysis

ACHN, Caki-2, and HUVEC cells were cultured in 90 mm dishes (6.0×10^5 cells/dish) for 3 days. Naftopidil, tamsulosin, or vehicle (0.1% DMSO) was added on day 2 and cell-cycle analysis was conducted 24 hours later by flow cytometry. Flow cytometry was conducted as described previously (7).

Preparation of cell lysates and Western blot analyses

ACHN, Caki-2, and HUVEC cells were cultured for 3 days in 90 mm dishes (6.0×10^5 cells/dish). Naftopidil, tamsulosin, or vehicle (0.1% DMSO) was added on day 2; cell lysates were prepared 24 hours later and analyzed by western blotting, as previously described (7). Western blots were probed with anti-p21 (1:1,000), anti-CDK2 (1:1,000), or anti- β -actin (1:5,000) antibodies and visualized on LAS-4000 Mini (Fuji Photo Film).

Animal studies

All animals were maintained in a pathogen-free environment, under experimental protocol guidelines approved by Mie University's Committee for Animal Investigations. Female athymic nude mice (BALB/c, nu/nu, 6–8 weeks old) were from CLEA Japan, Inc.

Subconfluent cultures of ACHN cells were trypsinized and 5×10^5 cells were counted and suspended. ACHN

tumors cells were grafted into female athymic nude mice (6–8 weeks old) divided into groups of 5. Animals were weighed twice weekly and treatments started 7 days after transplantation. Naftopidil (10 mg/kg/d) suspension in 0.5% carboxymethylcellulose or vehicle control was administered orally through a 22-gauge gavage needle for 28 days, as previously described (8).

Twenty patients diagnosed with clear cell RCC underwent radical nephrectomy or partial nephrectomy between December 2011 and December 2012 in Mie University Hospital (Mie, Japan). The institutional review board at the institution approved the study and informed consent was obtained from all patients. Specimens of 2 mm³ were prepared from 20 fresh RCC patient tissues obtained at the time of surgery. Of these, 12 to 16 specimens were grafted into the bilateral renal capsule. Animals were weighed twice weekly and treatments started 7 days after transplantation. Naftopidil (10 mg/kg/d) suspension in 0.5% carboxymethylcellulose or vehicle control was administered orally through a 22-gauge gavage needle for 28 days.

Histology and immunohistochemistry

Tumors were harvested from animals on day 35 after grafting, fixed in buffered formalin, and embedded in paraffin. Tissue slices (3 μ m) were stained with hematoxylin and eosin, and tissue morphology was visualized. Tissue




Figure 2. Effects of naftopidil on tumorigenesis *in vivo* in ACHN RCC cells. A, top: comparison of tumor weights from ACHN cells treated with vehicle control or with naftopidil (10 mg/kg) after grafting into animals. ACHN tumors cells were grafted into female athymic nude mice (6 to 8 weeks old) divided into groups of 5. The tumor weights were measured 35 days after transplanting. Bottom: gross appearance of tumors grafted into the renal capsule. B, Ki-67 index in ACHN cells after treatment with naftopidil. Ki-67 staining was used to assess cell proliferation at $\times 400$, magnifications. C, MVD in ACHN tumors. CD31-positive vessels with lumens were counted in 8 to 10 different areas at $\times 200$, magnifications. D, p21 cip1 index in ACHN cells after treatment with naftopidil. p21 cip1 staining was used to assess cell-cycle at $\times 400$, magnifications. E, CDK2 index in ACHN cells after treatment with naftopidil. CDK2 staining was used to assess cell-cycle at $\times 400$, magnifications. Values represent the mean \pm SD. Arrow: CD31-positive vessels with lumens. *, $P < 0.05$; **, $P < 0.01$ versus vehicle-treated control.

samples from ACHN tumors were analyzed for altered patterns of tumor cell proliferation (percent Ki-67 positivity), MVD (CD31-positive microvessels), and cell-cycle (percent p21cip1 or CDK2 positivity) between control and naftopidil-treated animals by immunohistochemical staining as previously described (7).

Matrigel plug assay

Matrigel (BD Biosciences) was injected subcutaneously into the flanks of nude mice (BALB/c, nu/nu, 6–8 weeks old), divided into groups of 5 each. Treatment began 1 day after transplantation with naftopidil or control vehicle, administered orally (10 mg/kg/d), for 55 days. After 56 days, the mice were perfused with PBS containing 2 mmol/L EDTA for 40 minutes after intravenous injection with 1% Evans blue dye and the amount of Evans blue eluted with formamide from the Matrigel plugs was measured with a spectrophotometer (620 nm), as previously described (13).

Statistical analysis

Unless otherwise stated, a minimum of 3 independent experiments were carried out for all quantitative studies and data are expressed as the mean \pm SD. Statistically significant differences between treatment and control groups were determined using one-way ANOVA and Tukey Multiple Comparison Test, and the correlation between RCC preoperative tumor characteristics and MVD ratio was determined using Student *t* test and Pearson correlation coefficient (PCC) test, followed by data analysis with JMP version 8.01. *P* values less than 0.05 were considered significant.

Results

Growth inhibition of ACHN and Caki-2 cells by naftopidil or tamsulosin

To investigate the effects of naftopidil and tamsulosin on RCC cells *in vitro*, ACHN and Caki-2 cells were treated as described in the Materials and Methods. Naftopidil exerted more cytotoxic effect than tamsulosin, which had a slight dose-dependent, cytotoxic effect on ACHN and Caki-2 cells (Fig. 1A).


To determine the mechanism by which naftopidil inhibits proliferation in RCC cells, we examined propidium iodide-stained cells by flow cytometry. Compared with vehicle, naftopidil increased the population of cells in G_1 phase and decreased the cell populations in S and G_2 (Fig. 1B); no appreciable change was observed between tamsulosin treatment and vehicle.

To determine which key cell-cycle regulators are involved in naftopidil-induced G_1 arrest, we investigated the expression of positive and negative G_1 -S checkpoint modulators in ACHN and Caki-2 cells, by western blot analysis (Fig. 1C). In ACHN and Caki-2, naftopidil increased p21cip1 and decreased CDK2, whereas tamsulosin caused no appreciable change in the levels of p21cip1 and CDK2.

Tumor growth delay of ACHN xenograft by oral administration of naftopidil

We analyzed the effects of naftopidil *in vivo* using subcutaneous ACHN xenograft tumors in BALB/c nude mice (Fig. 2A). Naftopidil induced a significant delay in tumor growth ($P < 0.05$).

Figure 3. Antiangiogenic effects of naftopidil on the Matrigel plug assay and on HUVEC cells. **A**, the functional role of naftopidil in mediating angiogenesis as assessed using an *in vivo* Matrigel plug assay. The amount of Evans blue dye was quantified by A_{620} and normalized to Matrigel weight. **B**, survival of HUVEC cells treated with naftopidil (0, 2.5, 5, 10, 20, 30, and 40 $\mu\text{mol/L}$) for 5 days. **C**, distribution of cell-cycle phases of HUVEC cells treated with 50 $\mu\text{mol/L}$ of each α_1 -AR antagonist for 24 hours. **D**, western blot of p21 in 30 μg of total lysates, from naftopidil and tamsulosin-treated HUVEC cells. p21 levels were shown with β -actin loading control. Values represent the mean \pm SD. *, $P < 0.05$; **, $P < 0.01$ compared with untreated controls.



The Ki-67 proliferation index was determined, using fixed tumor sections to better understand the mechanism mediating the tumor growth delay. As shown in Fig. 2B, naftopidil caused an approximate 50% reduction in proliferating cells, compared with vehicle control ($P < 0.01$). The MVD was significantly decreased in naftopidil-treated tumors, as shown in Fig. 2C, with an approximate 75% reduction in proliferating cells, compared with vehicle-treated tumors ($P < 0.01$). Naftopidil treatments also significantly increased the abundance of p21cip1 (Fig. 2D) and decreased the abundance of CDK2 (Fig. 2E) in ACHN tumors.

Analyses of antiangiogenic effects of naftopidil on the Matrigel plug assay and on HUVEC cells

To further address the functional role of naftopidil in mediating angiogenesis, we used an *in vivo* Matrigel plug assay. Naftopidil treatment markedly attenuated neovascularization (Fig. 3A). Evans blue was used to quantify the extent of neoangiogenesis. The naftopidil group (10 mg/kg/day) showed a reduction of about 35% in Evans blue content (Fig. 3A).

Naftopidil, at 2.5 $\mu\text{mol/L}$ dose or higher, suppressed cell proliferation of HUVEC cells in a dose-dependent manner (Fig. 3B). The number of naftopidil-treated HUVEC cells in G_1 phase was higher than for untreated HUVEC cells

(Fig. 3C). Naftopidil treatment increased p21cip1 in dose-dependent manner, whereas tamsulosin treatment showed the least change (Fig. 3D).

Establishment and analysis of RCC xenografts in nude mice

To develop an adoptive-transfer murine model to study the effects of naftopidil on RCC tumor progression, RCCs from a total of 20 patients were grafted into nude mice. MVD was significantly decreased in naftopidil-treated mice (Table 1 and Fig. 4B). PCC test showed strong positive correlations between the naftopidil/control MVD ratio and preoperative greatest tumor dimension that were measured by a pathologist after formalin-fixed (Table 2), whereas no appreciable association was observed between naftopidil/control MVD ratio and age, sex, Fuhrman grade, or initial MVD of RCC.

Discussion

Cell-cycle inhibition is a potentially important target for cancer management, because there is an established association between deregulated cell-cycle progression and cancer (14, 15). This antiproliferative effect suggests the potential value of naftopidil in RCC therapy. Cyclin-dependent kinases (CDK; e.g., CDK2) are critical, positive

Table 1. Patient characteristics and analysis of RCC tumors grafted into nude mice

cRCC Patients characteristics						
Patient number	Age	Sex	Fuhrman grade	Tumor greatest dimension (mm)	MVD of RCC (number/field)	Naftopidil/control CD31 positive MVD ratio
1	76	M	2	25	3.4 \pm 1.1	0.57
2	69	M	3	31	4.8 \pm 0.4	0.38
3	66	F	3	30	6.8 \pm 0.3	0.58
4	84	F	3	30	5.0 \pm 0.3	0.46
5	57	M	2	20	5.0 \pm 0.6	0.63
6	41	M	2	60	4.6 \pm 0.5	0.47
7	69	M	2	28	4.6 \pm 1.0	0.36
8	81	M	2	37	4.0 \pm 0.6	0.67
9	34	M	2	50	5.0 \pm 0.6	0.66
10	60	M	3	75	6.2 \pm 0.9	0.71
11	76	M	3	35	7.7 \pm 1.6	0.34
12	80	M	3	65	8.4 \pm 3.1	0.53
13	79	F	2	44	5.5 \pm 0.7	0.44
14	66	M	2	26	4.4 \pm 0.4	0.21
15	60	M	3	35	8.0 \pm 2.2	0.44
16	66	M	3	55	7.7 \pm 1.7	0.62
17	70	F	2	11	7.7 \pm 1.4	0.34
18	78	M	2	55	5.5 \pm 1.1	0.61
19	73	F	2	22	4.4 \pm 0.8	0.18
20	77	F	2	39	4.5 \pm 0.6	0.36

NOTE: Demographics and MVD ratios of patients whose tumors were used in RCC xenografts. Twenty patients diagnosed with RCC underwent radical nephrectomy or partial nephrectomy. All patient with RCC tissues were obtained at the time of surgery and grafted into the bilateral renal capsule. All different RCC specimens remained engrafted successfully 35 days after transplantation. Values represent the mean \pm SD.




Figure 4. Gross appearances of RCC xenografts and relationships of MVD of RCC xenografts between control and naftopidil groups. A, gross appearance of tumors grafted into the renal capsule. Arrow: engrafted yellow RCC tumors grafted after 35 days. B, relationships of MVD of RCC xenografts between control and naftopidil groups.

regulators of progression through the cell-cycle G_1 -S checkpoint (16). CDK inhibitors of the Kip1/Cip1 and INK4 families prevent activation of CDKs and their entry into S-phase in mammalian cells (17). p21 (cip1/waf1) is a CKI that directly inhibits the activity of cyclin E/CDK2 complexes and p21 functions as a regulator of cell-cycle progression at S-phase (18). Our study showed that expression of p21cip1 was significantly increased in ACHN and Caki-2 cells by naftopidil treatment but was not affected by tamsulosin treatment (Fig. 1C); expression of CDK2 was significantly decreased by naftopidil treatment. These results indicate that naftopidil-induced G_1 cell-cycle arrest is mainly associated with p21cip1 levels in ACHN and Caki-2 cells. Furthermore, it was the same results with *in vivo* ACHN xenograft model (Fig. 2D and E).

Targeting angiogenesis in patients with advanced and/or metastatic RCC has become the standard of care. The use of

targeted therapies, including angiogenesis inhibitors, TKIs, and mTOR inhibitors, has contributed to increased progression-free survival and overall survival in patients with RCC (19–21). However, these therapies are often not curative and produce a range of adverse effects and the majority of patients develop recurrent disease. Therefore, it is important to continue investigating novel treatment approaches that may potentially improve treatment outcome in RCC. In the present study, naftopidil inhibited the proliferation of HUVEC cells by inducing G_1 cell-cycle arrest *in vitro* and neovascularization *in vivo*. Here, we have shown that naftopidil plays a critical role in endothelial cell growth *in vitro* and angiogenesis *in vivo*. Moreover, our immunohistochemistry in RCC xenograft model results provide supportive evidence that naftopidil suppressed neovascularization. The steps leading to creation of new blood vessels include activation of endothelial cells that form the blood vessel wall, synthesis of matrix metalloproteinases that break down the extracellular matrix, invasion through the matrix and endothelial cell proliferation. Eventually, new endothelial cells organize into hollow tubes, creating new networks of blood vessels that supply tissues (22). These processes are dynamically controlled by many proangiogenic and antiangiogenic factors. Normally, the vasculature is quiescent outside of select physiologic processes, such as wound repair and the female menstrual cycle (22). The turnover time of these cells may be several years (23). In contrast, endothelial cells during neovascularization can proliferate with a turnover time of several days (24). The understanding that the growth of tumors depends on angiogenesis has led to the development of novel strategies for treatment directed at the tumor vasculature. Antiangiogenic compounds have had striking success in preclinical models and new agents are rapidly entering clinical trials (22). In addition, targeted therapies, the only treatments currently available for RCC or metastatic RCC beside surgical resection, cause a number of adverse effects. Most adverse effects associated with TKIs and mTOR inhibitors may be managed effectively with medical or supportive measures (25). However, some toxicities can affect the patient's quality of life or present medical challenges in treating patients with comorbidities (25). For example, the TKIs sunitinib and sorafenib are commonly associated with hypertension, diarrhea, fatigue, hand-foot syndrome, thyroid dysfunction, elevated lipase, and myelosuppression (25).

The present study used 2 selective α_1 -AR antagonists: naftopidil, which has higher selectivity for α_{1D} -AR than tamsulosin and is marketed only in Japan (26), and tamsulosin, which is selective for α_{1A} -AR and α_{1D} -AR and is used worldwide (27). Clinically, α_1 -AR antagonists such as naftopidil and tamsulosin have been widely used to treat BPH, a common prostatic disease in elderly men; naftopidil has high tolerability with few adverse effects (28). As the incidence of BPH increases with age (29), this would suggest that administration of α_1 -AR antagonists for BPH might often precede diagnosis of RCC. Thus, there may be some prospective clinical benefits from long-term use of naftopidil for BPH. Naftopidil may also be considered for long-

Table 2. Association between RCC preoperative tumor characteristics and MVD ratio, using PCC

Feature	PCC	95% CI	P
Age at surgery	-0.2346	-0.61–0.23	0.31
Tumor greatest dimension	0.5296	0.11–0.78	0.01

NOTE: The calculations showed strong positive correlation between the naftopidil/control MVD ratio and preoperative tumor greatest dimension (PCC, 0.52; 95% CI, 0.11–0.78; $P = 0.01$).

term use to prevent RCC. Moreover, as naftopidil has been available clinically, it may be used in treating RCC without the costs associated with development of a new drug.

In conclusion, our present study suggests that naftopidil can suppress tumor growth and angiogenesis by inhibiting the growth of human RCC and vascular endothelial cells, through G₁ cell-cycle arrest. Naftopidil may be used, not only to better resolve urinary morbidities associated with BPH without compromising safety in elderly male patients (28), but also as an off-label drug to suppress development of RCC. However, additional studies are needed to verify the observed effects, using clinically appropriate doses, before naftopidil can be used to treat RCC in patients.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: Y. Iwamoto, K. Ishii, M. Kato, Y. Yamada, Y. Sugimura

Development of methodology: Y. Iwamoto, M. Kato, Y. Yamada

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): Y. Iwamoto, M. Kato, T. Shiraishi

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): Y. Iwamoto, M. Kato

Writing, review, and/or revision of the manuscript: Y. Iwamoto, K. Ishii, M. Kato

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): Y. Iwamoto, T. Sasaki, M. Kato, T. Shiraishi, Y. Sugimura

Study supervision: Y. Iwamoto, K. Ishii, M. Kato, K. Arima, T. Shiraishi, Y. Sugimura

Acknowledgments

The authors thank Ms. Yumi Yoshikawa for technical support and Dr. Tomomi Yamada, Department of the Translational Medical Science, Mie University Graduate of Medicine, for help with the statistical analyses.

Grant Support

This study was supported by Grants-in-Aid from the Ministry of Education for Science and Culture of Japan, no. 22591764 (to Y. Sugimura); no. 21592039 (to K. Arima); no. 21791499 (to K. Ishii), and Grants-in-Aid from the Okasan-Kato Bunkazaidan of Japan (to Y. Iwamoto).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received March 14, 2013; revised July 16, 2013; accepted July 18, 2013; published OnlineFirst July 30, 2013.

References

- Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, Weikert S, et al. The epidemiology of renal cell carcinoma. *Eur Urol* 2011;60:615–21.
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. *CA Cancer J Clin* 2009;59:225–49.
- Takeuchi A, Eto M, Tatsugami K, Yamada H, Oki T, Kiyoshima K, et al. Mechanism of synergistic antitumor effect of sorafenib and interferon-alpha on treatment of renal cell carcinoma. *J Urol* 2010;184:2549–56.
- Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, de Bruine AP. VHL and HIF signalling in renal cell carcinogenesis. *J Pathol* 2010;221:125–38.
- Lainakis G, Bamias A. Targeting angiogenesis in renal cell carcinoma. *Curr Cancer Drug Targets* 2008;8:349–58.
- Brugarolas J. Renal-cell carcinoma—molecular pathways and therapies. *N Engl J Med* 2007;356:185–7.
- Kanda H, Ishii K, Ogura Y, Imamura T, Kanai M, Arima K, et al. Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest. *Int J Cancer* 2008;122:444–51.
- Hori Y, Ishii K, Kanda H, Iwamoto Y, Nishikawa K, Soga N, et al. Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma. *Cancer Prev Res* 2011;4:87–96.
- Garrison JB, Shaw YJ, Chen CS, Kyprianou N. Novel quinazoline-based compounds impair prostate tumorigenesis by targeting tumor vascularity. *Cancer Res* 2007;67:11344–52.
- Harris AM, Warner BW, Wilson JM, Becker A, Rowland RG, Conner W, et al. Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. *J Urol* 2007;178:2176–80.
- Sakamoto S, Schwarze S, Kyprianou N. Anokis disruption of focal adhesion-Akt signaling impairs renal cell carcinoma. *Eur Urol* 2011;59:734–44.
- Yoshimura K, Tanimoto A, Abe T, Ogawa M, Yutsudo T, Kashimura M, et al. Shiga toxin 1 and 2 induce apoptosis in the amniotic cell-line WISH. *J Soc Gynecol Invest* 2002;9:22–6.
- Suehiro J, Hamakubo T, Kodama T, Aird WC, Minami T. Vascular endothelial growth factor activation of endothelial cells is mediated by early growth response-3. *Blood* 2010;115:2520–32.
- Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. *Genes Dev* 1999;13:1501–12.
- Jacks T, Weinberg RA. Cell-cycle control and its watchman. *Nature* 1996;381:643–4.
- Weinberg RA. The retinoblastoma protein and cell cycle control. *Cell* 1995;81:323–30.
- Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. *Genes Dev* 1995;9:1149–63.
- Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. *Cancer Res* 2005;65:3980–5.
- George S, Bukowski RM. Role of everolimus in the treatment of renal cell carcinoma. *Ther Clin Risk Manag* 2009;5:699–706.
- Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. *Oncologist* 2008;13:1084–96.
- van der Veldt AA, Haanen JB, van den Eertwegh AJ, Boven E. Targeted therapy for renal cell cancer: current perspectives. *Discov Med* 2010;10:394–405.
- Rosen L. Antiangiogenic strategies and agents in clinical trials. *Oncologist* 2000;5 Suppl 1:20–7.
- Folkman J. Angiogenesis: an organizing principle for drug discovery? *Nat Rev Drug Discov* 2007;6:273–86.
- Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. *Nat Rev Cancer* 2003;3:401–10.
- Mulders P. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms. *BJU Int* 2009;104:1585–9.
- Kawabe K. [Latest frontiers in pharmacotherapy for benign prostatic hyperplasia]. *Yakugaku Zasshi* 2006;126 Spec no.:199–206.
- Ventura S, Oliver V, White C, Xie J, Haynes J, Exintaris B. Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH). *Br J Pharmacol* 2011;163:891–907.
- Yokoyama T, Kumon H, Nasu Y, Takamoto H, Watanabe T. Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study. *Int J Urol* 2006;13:932–8.
- Alcaraz A, Hammerer P, Tubaro A, Schroder FH, Castro R. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. *Eur Urol* 2009;55:864–73.